Qoolabs

Executive Summary

Qoolabs is a US-based biotechnology company specializing in the discovery and development of rabbit monoclonal antibodies using its proprietary QMAb platform. Founded in 2018 and headquartered in San Francisco, the company offers high-affinity, specific antibodies for research, diagnostic, and therapeutic applications. Qoolabs provides both custom antibody development services and a catalog of pre-made antibodies, positioning itself as a versatile player in the antibody market. The company's rabbit monoclonal technology offers advantages in affinity and specificity compared to traditional murine antibodies, enabling applications in complex diagnostic assays and targeted therapeutics. Despite operating in a competitive landscape, Qoolabs differentiates itself through its proprietary platform and focus on rabbit-derived antibodies. However, the company remains private with limited publicly disclosed funding or revenue data, and its profile is not yet widely recognized in major industry databases. To achieve growth, Qoolabs will need to secure partnerships, expand its product catalog, and potentially seek regulatory approvals for diagnostic or therapeutic products.

Upcoming Catalysts (preview)

• Q4 2026Launch of Expanded Pre-Made Antibody Catalog70% success
• Q2 2027Diagnostic Partnership for Rabbit Monoclonal Antibodies50% success
• Q4 2027Therapeutic Antibody Collaboration with Pharma30% success